Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Ublituximab has demonstrated a clear clinical advantage over teriflunomide in reducing the number of relapses in patients with relapsing forms of multiple sclerosis. Although it has not been directly compared to ocrelizumab and ofatumumab, indirect comparisons suggest comparable efficacy. This evidence supports a significant improvement in primary outcomes, justifying the A+ rating.
Cost effectiveness
Ublituximab is indicated as a cost-effective option compared to existing treatments like ocrelizumab and ofatumumab, with a favorable cost comparison suggesting it offers similar benefits at a lower cost. This aligns with the A+ rating for cost-effectiveness.
Quality of life
While the document does not provide specific HRQoL data, the recommendation for ublituximab implies a positive impact on patients’ quality of life due to its effectiveness in reducing relapses. This suggests moderate improvements in HRQoL, warranting an A rating.
Supporting Domains
Safety and Adverse Effects
The document does not detail specific adverse effects, but the recommendation implies an acceptable safety profile. Given that ublituximab is positioned alongside other established therapies, it suggests manageable adverse events, justifying an A rating.
Comparator Selection
Ublituximab has not been directly compared to ocrelizumab and ofatumumab in clinical trials, which presents a limitation. However, the use of indirect comparisons provides some context, leading to a B++ rating for comparator selection.
Patient Population and Subgroups
The indication for ublituximab targets adults with relapsing forms of multiple sclerosis, which is a well-defined patient population. The document suggests that the treatment is appropriate for a broad range of patients within this group, supporting an A+ rating.
Care Pathway Integration
Ublituximab can be integrated into existing treatment pathways for multiple sclerosis without significant disruption, as it is similar to other therapies already in use. This ease of integration supports an A+ rating.
Resource Use and Cost Implications
The document indicates that ublituximab is available at a discounted price, which suggests a manageable budget impact. This aligns with the A rating for resource use and cost implications.
Evidence Quality and Robustness
The evidence supporting ublituximab includes clinical trial data and indirect comparisons, which provide a robust foundation despite some limitations in direct head-to-head trials. This supports an A rating for evidence quality.
Uncertainty, Sensitivity, and Broader Impacts
The recommendations are based on a thorough evaluation of available evidence, with manageable uncertainties regarding the treatment’s effectiveness compared to existing options. This context supports an A rating.
